Frequently Asked Questions

Volunteers are not paid for taking part in this Alzheimer’s research. However, the sponsor will reimburse reasonable travel expenses for you and your study partner for each visit.

A study partner is someone who accompanies the participant on some study visits and can answer questions about the volunteer’s symptoms. The study partner should be someone who sees the volunteer regularly (e.g., a spouse, relative, or close friend) as they will need to inform us about any potential changes in the volunteer’s health or behavior. The number of visits he or she needs to attend depends on each study.

This depends on the research study. The screening portion of the study is generally when the visits are most frequent. This is when all initial screening is conducted to confirm whether a volunteer is eligible for a study. During the treatment stage of the study, the visits will be less frequent. Some studies require a Center visit once a month; other studies require a visit every six weeks. If you enroll in a study, we will be able to give you all of your appointments in advance.

It depends on clinical trial you are eligible for. We also provide Biomarker and observational studies that does not require taking a drug.

No. You will not know whether you are taking the active study drug or a placebo. A placebo is a similar-looking tablet but doesn’t contain any active drug. You will be randomly assigned to a study groups and you and your study team will not know which group you are in. This is called a randomized, double-blind, placebo-controlled trial.

There is a chance you will be in the placebo group. The probability will depend on the trial and will range from a 50% to a 30% placebo group. Whichever group you are in, you will still benefit from the ongoing medical care and psychometric testing you will receive as part of the trial. At the end of the trial period, most trials offer the opportunity for you to enter the “open label extension”. This is when you continue in the trial on the active drug despite whichever group (placebo or active drug) you were in previously. The open-label extension is un-blinded, so you will know you are on the active drug.

Any potential side effects will be listed in the patient information sheets sent to you prior to your initial consultation. Most side effects are non-specific, but some trials have specific side effects that your study doctor will discuss with you. If you have a primary care physician, we will work closely with him or her – and you – to ensure your safety at all times.

Absolutely. Leaving a study does not affect your medical or legal rights. It is not necessary to give us a reason as to why you want to leave, although we always value any feedback. If you choose to leave after you have started taking the study drug, we are obligated to offer you a closing visit to carry out final medical investigations to ensure your safety.

Every FDA-approved medication you’ve ever taken has gone through a clinical trial and safety is always the #1 priority.

1. Free medical care
2. Access to medical professionals
3. To learn more about their disease
4. Receive regular updates about the research while they’re enrolled
5. Receive information about the study results after the study has ended
6. To feel part of a community

Participant health is MOST important to the medical professionals who conduct clinical trials. Nothing will be done that may put you at risk. We strive to offer world-class medical help to those who participate.

Clinical trials have a regulatory and ethical framework to protect participants. In fact, they are one of the most regulated industries. Similar to that of aviation and finance.

Clinical trials have a regulatory and ethical framework to protect participants. Speaking to a study specialist can help to determine if you may be a candidate.

All clinical trials have rules about who can and cannot participate.

Participation involves NO cost and may involve payment.

Clinical trials take place in different settings. Universities, Hospitals, Physicians Office, or Private Clinical Trial Centers. Regardless of where you go, the clinical trial protocol will be EXACTLY the same.

The majority of clinical trial participants would do it again. A recent Nationwide survey of clinical trial participants showed that 98% of participants would do it again and 92% felt the experience met or exceeded their expectations

We conduct a diverse range of clinical trials, encompassing investigational products in different forms such as oral tablets, IV infusions, subcutaneous injections, and intrathecal administrations.

Alzheimer’s Disease is a neurodegenerative condition that primarily affects cognitive functions, particularly memory. Yes, Re:Cognition Health is actively involved in research related to Alzheimer’s Disease, including clinical trials aimed at developing new treatments and interventions.

Absolutely. At Re:Cognition Health, we conduct clinical trials for a wide range of brain and mind-related diseases, including but not limited to dementia, Parkinson’s Disease, multiple sclerosis, and psychiatric disorders such as depression and schizophrenia.

Each clinical trial has specific eligibility criteria based on factors such as age, medical history, and current health status. To determine your eligibility, we conduct thorough screenings prior to enrollment. You can find more information about eligibility criteria for each trial on our website or by contacting us directly.

Participating in a clinical trial involves a commitment to attending scheduled study visits, undergoing medical assessments, and adhering to the study protocol. Throughout the trial, you will receive close monitoring from our experienced medical team, and your safety and well-being are our top priorities.

Re:Cognition Health adheres strictly to ethical guidelines and regulatory standards set forth by organizations such as the FDA and Institutional Review Boards (IRBs). Our clinical trials are conducted with the utmost attention to patient safety, and we prioritize transparency and integrity in all aspects of our research.

We encourage you to visit our website regularly for updates on ongoing clinical trials, research findings, and news related to brain and mind health. You can also follow us on social media platforms and subscribe to our newsletter to stay informed.

Re:Cognition Health is pleased to announce that we are in the process of expanding access to FDA-approved medications for Alzheimer’s Disease, such as Lecanemab. We anticipate welcoming patients to benefit from these treatments in the near future. We encourage you to visit our website regularly for updates on this exciting development.